SCHEMBL4630563

SCHEMBL4630563

CCC(=O)ON1CCCCC1C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CHRM2 P08172 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
SCN1A P35498 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN3A Q9NY46 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27517307 0.79 HPGD (0.41) HPGDGAAKMT2AMEN1TSHR
Hydrochloric Acid SCHEMBL27976853 0.79 ALDH1A1 (0.38) HPGDGAAKMT2AMEN1TSHR
SCHEMBL30368493 0.78 NAAA (0.39) KMT2AMEN1TSHRHRH3SMN1; SMN2
SCHEMBL3191846 0.77 DPP4 (0.44)
SCHEMBL3179806 0.77
SCHEMBL489632 0.76 GAA (0.39) HPGDGAAKMT2AMEN1TSHR
SCHEMBL25547479 0.75 CHRM2 (0.33) SMN1; SMN2CHRM2ALDH1A1CHRM4CHRM1
SCHEMBL27630857 0.75 HPGD (0.38) HPGDGAAKMT2AMEN1TSHR
SCHEMBL28849318 0.74 HPGD (0.37) HPGDGAAKMT2AMEN1TSHR
SCHEMBL27668050 0.74 SMN1; SMN2 (0.33) GAATSHRSMN1; SMN2CHRM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9788784-B2 Accelerated evaluation of treatments to prevent clinical onset of neurodegenerative diseases BANNER HEALTH (US) 2017-10-17 US disclosed
US-20170042476-A1 ACCELERATED EVALUATION OF TREATMENTS TO PREVENT CLINICAL ONSET OF NEURODEGENERATIVE DISEASES BANNER HEALTH 2017-02-16 US disclosed
US-9492114-B2 Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease Banner Health Systems, Inc. (US) 2016-11-15 US disclosed
US-20150080703-A1 ACCELERATED EVALUATION OF TREATMENTS TO PREVENT CLINICAL ONSET OF ALZHEIMER'S DISEASE BANNER HEALTH 2015-03-19 US disclosed
EP-1761191-A4 EVALUATION OF A TREATMENT TO DECREASE THE RISK OF A PROGERESSIVE BRAIN DISORDER OR TO SLOW BRIAN AGING BANNER HEALTH (US) 2008-05-14 EP disclosed
EP-1761191-A2 EVALUATION OF A TREATMENT TO DECREASE THE RISK OF A PROGERESSIVE BRAIN DISORDER OR TO SLOW BRIAN AGING Banner Health (US) 2007-03-14 EP disclosed
WO-2006009887-A2 EVALUATION OF BRAIN TREATMENT BANNER HEALTH (US) 2006-01-26 WO disclosed
US-20050283054-A1 Evaluation of a treatment to decrease the risk of a progressive brain disorder or to slow brain aging BANNER HEALTH 2005-12-22 US disclosed